13 May, 2025 in Investor Relations Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer’s Program Amid Encouraging Data
06 May, 2025 in Investor Relations Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering
05 May, 2025 in Investor Relations Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock
01 May, 2025 in Investor Relations Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback
24 April, 2025 in Investor Relations Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia
23 April, 2025 in Investor Relations Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management
21 April, 2025 in Investor Relations Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices
14 April, 2025 in Investor Relations Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders
02 April, 2025 in Investor Relations Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial
26 March, 2025 in Investor Relations Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on April 3
